Elanco Animal Health Inc · Soliciting Materials filed pursuant to Rule 14a-12 by Ancora Holdings Group, LLC et al. · Filed February 29, 2024 · File No. 001-38661
We note your repeated references to your expectations about what the company will claim (pages 6 and 8). It is unclear how you are able to predict what the company will claim or say. Please provide support for your statements or confirm that you will refrain from making similar statements in future filings.
No reply letter found.
Each statement or assertion of opinion or belief must be clearly characterized as such, and a reasonable factual basis must exist for each such opinion or belief. Support for opinions or beliefs should be self-evident, disclosed in the proxy statement or provided to the staff on a supplemental basis. With a view toward revised disclosure, provide support for your statements: • in each of the six boxes on page 11.Rest of the question
• that the company overpaid in the Bayer acquisition (page 19). • that Mr. Simmons has failed to execute on revenue growth, growth margin, EBITDA margin, leverage and free cash flow since the company's IPO (page 19). In this respect, we note that later slides refer to estimated 2024 results while the referenced statement presents your view as to historical results. • that the company "continues to disingenuously highlight EBITDA improvement" (page 24). • that "net working capital has become a meaningful drag" (page 25). • that proxy advisory firms have recommended against the election of incumbent directors (page 27).
No reply letter found.
Avoid issuing statements in your proxy statement that directly or indirectly impugn the character, integrity or personal reputation or make charges of illegal, improper or immoral conduct without factual foundation. Disclose the factual foundation for such assertions or delete the statements. In this regard, note that the factual foundation for such assertions must be reasonable. Refer to Rule 14a-9.Rest of the question
Please provide us supplementally the factual foundation for your disclosures that "The Board is clearly committed to ignoring the will of shareholders, underscoring its culture of entrenchment." (page 27)
No reply letter found.
Please provide us supplemental support for the disclosure in the last bullet point on page 28.
No reply letter found.